[go: up one dir, main page]

PL1778239T3 - Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena - Google Patents

Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena

Info

Publication number
PL1778239T3
PL1778239T3 PL05762145T PL05762145T PL1778239T3 PL 1778239 T3 PL1778239 T3 PL 1778239T3 PL 05762145 T PL05762145 T PL 05762145T PL 05762145 T PL05762145 T PL 05762145T PL 1778239 T3 PL1778239 T3 PL 1778239T3
Authority
PL
Poland
Prior art keywords
adenosine
syndrome
treatment
receptor agonists
dry eye
Prior art date
Application number
PL05762145T
Other languages
English (en)
Inventor
Pnina Fishman
Ilana Lorber
Ilan Cohn
Tatiana Reitblat
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of PL1778239T3 publication Critical patent/PL1778239T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05762145T 2004-07-28 2005-07-18 Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena PL1778239T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59162804P 2004-07-28 2004-07-28
EP05762145.0A EP1778239B1 (en) 2004-07-28 2005-07-18 Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
PCT/IL2005/000762 WO2006011130A1 (en) 2004-07-28 2005-07-18 Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren’s syndrome

Publications (1)

Publication Number Publication Date
PL1778239T3 true PL1778239T3 (pl) 2014-01-31

Family

ID=34979400

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05762145T PL1778239T3 (pl) 2004-07-28 2005-07-18 Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena

Country Status (6)

Country Link
EP (1) EP1778239B1 (pl)
JP (1) JP4642847B2 (pl)
DK (1) DK1778239T3 (pl)
ES (1) ES2432113T3 (pl)
PL (1) PL1778239T3 (pl)
WO (1) WO2006011130A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2622975C (en) * 2006-01-27 2011-05-03 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
RU2457209C2 (ru) 2006-04-21 2012-07-27 Новартис Аг Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
PL2137202T3 (pl) 2007-03-14 2017-12-29 Can-Fite Biopharma Ltd. Sposób syntezy IB-MECA
JP5408882B2 (ja) * 2008-01-23 2014-02-05 ヤマサ醤油株式会社 唾液分泌促進剤
PT2794627T (pt) 2011-12-22 2018-12-19 Janssen Biopharma Inc Nucleósidos substituídos, nucleótidos e análogos dos mesmos
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2953950B1 (en) 2013-02-11 2021-01-13 The Regents of The University of California Compositions and methods for treating neurodegenerative diseases
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US11414419B2 (en) 2017-06-21 2022-08-16 Mitokinin, Inc. Substituted purines for the treatment of neurodegenerative and mitochondrial diseases
CN114057742A (zh) * 2021-11-03 2022-02-18 高颜苑科技(深圳)有限责任公司 一种用于修复角膜损伤的mettl3抑制剂及其药物应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
ATE206432T1 (de) * 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
WO1999006053A1 (en) * 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine

Also Published As

Publication number Publication date
ES2432113T3 (es) 2013-11-29
JP2008508256A (ja) 2008-03-21
WO2006011130A1 (en) 2006-02-02
EP1778239B1 (en) 2013-08-21
JP4642847B2 (ja) 2011-03-02
EP1778239A1 (en) 2007-05-02
DK1778239T3 (da) 2013-12-02

Similar Documents

Publication Publication Date Title
PL1778239T3 (pl) Agoniści receptora adenozynowego A3 do leczenia zaburzeń suchego oka w tym zespołu Sjogrena
PL374700A1 (pl) Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka
WO2005097140A3 (en) Selective antagonists of a2a adenosine receptors
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
PT1833799E (pt) Derivados de 3-fenil-pirazole como moduladores do receptor 5-ht2a de serotonina úteis no tratamento de desordens que lhe estão relacionadas
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
IL191283A (en) Compositions for treating eye irregularities
NO20054343D0 (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
IL180371A0 (en) Method of treating sjogren's syndrome
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
IL182365A0 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
ZA200701876B (en) Stable suspension formulations of erythoropoietin receptor agonists
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
IL183310A0 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
EP1895840A4 (en) P2Y6 RECEPTOR AGONISTS FOR THE TREATMENT OF LUNG DISEASES
IL195431A0 (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
IL191271A0 (en) Adenosine a3 receptor agonists for the treatment of dry eye disorders
HK1098155A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
ZA200802552B (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
EP2064347A4 (en) METHODS FOR THE IDENTIFICATION, EVALUATION AND TREATMENT OF PATIENTS WITH DC CHIMIOKINE RECEPTOR 2 (CCR-2) MEDIATION DISORDERS